Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 12/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3R2 | O00459 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2778213 | 0.91 | PIK3CG (0.44) | PIK3CGPIK3CDPIK3R1PIK3CBPIK3CA | |
| SCHEMBL734677 | 0.90 | PIK3CG (0.50) | PIK3CGPIK3CDCNR2PIK3R1PIK3CB | |
| SCHEMBL6757118 | 0.89 | PIK3CG (0.44) | PIK3CGPIK3CDPIK3R1PIK3CBPIK3CA | |
| SCHEMBL734154 | 0.86 | PIK3CG (0.46) | PIK3CGPIK3CDPIK3R1PIK3CBPIK3CA | |
| SCHEMBL735460 | 0.84 | PIK3CG (0.46) | PIK3CGPIK3CDPIK3R1PIK3CBPIK3CA | |
| SCHEMBL735492 | 0.84 | PIK3CG (0.46) | PIK3CGPIK3CDPIK3R1POLB | |
| SCHEMBL734675 | 0.82 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3R1PIK3CBPOLB | |
| SCHEMBL7164778 | 0.82 | PIK3CG (0.49) | PIK3CGPIK3CDPIK3R1PIK3CBPIK3CA | |
| SCHEMBL6757116 | 0.80 | PIK3CG (0.40) | PIK3CGPIK3CDPIK3R1PIK3CBPIK3CA | |
| SCHEMBL735319 | 0.78 | PIK3CD (0.39) | PIK3CGPIK3CDCNR2PIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140154772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2014-06-05 | — | — | US | claimed |
| EP-1278748-B1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2011-03-23 | — | — | EP | claimed |
| EP-1885356-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2008-02-13 | — | — | EP | claimed |
| EP-1755609-A1 | METHODS FOR TREATING AND/OR PREVENTING ABERRANT PROLIFERATION OF HEMATOPOIETIC CELLS | ICOS CORPORATION (US) | 2007-02-28 | — | — | EP | claimed |
| EP-1750715-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2007-02-14 | — | — | EP | claimed |
| EP-1750714-A1 | PHOSPHOINOSITIDE 3-KINASE DELTA SELECTIVE INHIBITORS FOR INHIBITING ANGIOGENESIS | VANDERBILT UNIVERSITY (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2006089106-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2006-08-24 | — | — | WO | claimed |
| US-20060106038-A1 | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells | ICOS CORPORATION (US) | 2006-05-18 | — | — | US | claimed |
| US-20060079538-A1 | Methods for inhibiting angiogenesis | VANDERBILT UNIVERSITY | 2006-04-13 | — | — | US | claimed |
| WO-2005120511-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2005-12-22 | — | — | WO | claimed |
| US-20050239809-A1 | Methods for treating and preventing hypertension and hypertension-related disorders | MICHIGAN STATE UNIVERSITY | 2005-10-27 | — | — | US | claimed |
| WO-2005067901-A2 | METHODS FOR TREATING AND PREVENTING HYPERTENSION AND HYPERTENSION-RELATED DISORDERS | MICHIGAN STATE UNIVERSITY (US) | 2005-07-28 | — | — | WO | claimed |
| US-20050054614-A1 | Methods of inhibiting leukocyte accumulation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-10 | — | — | US | claimed |
| US-20050043239-A1 | Methods of inhibiting immune responses stimulated by an endogenous factor | ICOS CORPORATION | 2005-02-24 | — | — | US | claimed |
| WO-2005016349-A1 | METHODS OF INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| WO-2005016348-A1 | METHOD OF INHIBITING IMMUNE RESPONSES STIMULATED BY AN ENDOGENOUS FACTOR | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-20040266780-A1 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | ICOS CORPORATION | 2004-12-30 | — | — | US | claimed |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION | 2003-10-16 | — | — | US | claimed |
| US-6518277-B1 | Disrupting leukocyte function | ICOS CORPORATION | 2003-02-11 | — | — | US | claimed |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION, A DELAWARE CORPORATION | 2002-10-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054614-A1 | Methods of inhibiting leukocyte accumulation | PI4KB, PIK3CD, PIK3CA | PIK3CG 7/4885PIK3CD 2/4885CNR2 3548/4885 |
| US-20140154772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PIK3CG 3/4885PIK3CD 1/4885CNR2 2956/4885 |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | PIK3CD, PIK3CA, PIK3CG | PIK3CG 3/4885PIK3CD 1/4885CNR2 1751/4885 |
| US-20060079538-A1 | Methods for inhibiting angiogenesis | FLT4, KDR, PDGFRB | PIK3CG 13/4885PIK3CD 6/4885CNR2 2399/4885 |
| US-20040266780-A1 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | PIK3CD, PIK3CA, PIK3CG | PIK3CG 3/4885PIK3CD 1/4885CNR2 3796/4885 |
| US-20050239809-A1 | Methods for treating and preventing hypertension and hypertension-related disorders | PRKCH, PTEN, PRKCA | PIK3CG 6/4885PIK3CD 4/4885CNR2 861/4885 |
| US-20050043239-A1 | Methods of inhibiting immune responses stimulated by an endogenous factor | PI4KB, PI4KA, PIK3CD | PIK3CG 10/4885PIK3CD 3/4885CNR2 2035/4885 |
| US-20060106038-A1 | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells | MCL1, NFATC1, MKI67 | PIK3CG 57/4885PIK3CD 25/4885CNR2 2769/4885 |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | PIK3CG 3/4885PIK3CD 1/4885CNR2 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.